Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cinclus Pharma Holding AB ( (SE:CINPHA) ) has provided an update.
Cinclus Pharma has received positive feedback from the FDA regarding its Chemistry, Manufacturing, and Controls (CMC) meeting, which supports the advancement of its lead product, linaprazan glurate. This feedback is a significant milestone in the company’s regulatory process, reinforcing its confidence in its manufacturing strategy and regulatory readiness, and ensuring continued progress in its development timeline.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing treatments for acid-related diseases and upper gastrointestinal disorders. Its leading drug candidate, linaprazan glurate, aims to effectively treat gastroesophageal reflux disease (GERD) and has undergone extensive clinical trials.
Average Trading Volume: 66,659
Technical Sentiment Signal: Sell
Learn more about CINPHA stock on TipRanks’ Stock Analysis page.